anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Noise-Induced Hearing Loss (NIHL) is a condition caused by repeated exposure to loud noise, with operating theatre personnel potentially at risk. The aims of this study were to establish the typical noise levels in orthopaedic theatres and to compare these to The Control of Noise at Work Regulations 2005.
MATERIALS AND METHODS: We measured the average noise levels in 40 trauma and orthopaedic surgeries in a single centre. We used the Decibel X app to take measurements, then performed corrections to ascertain noise levels at the surgeon's ear (Leq). The daily noise exposure level for theatre staff for each procedure (LEP, d) and the LEP, d over an average 8-hour working day when performing different groups of procedures were calculated. Data were analysed using descriptive statistics, ANOVA, t-test and the Pearson coefficient of correlation.
RESULTS: The LEP, d lower action value (80 dBA) as set by the Health and Safety Executive (HSE) was met by performing a single revision total knee replacement or a right open ankle debridement. Assuming three procedures are conducted per list, lists consisting of joint replacements (82 dBA) or medium elective procedures (81 dBA) exceed this lower limit. Additionally, lists comprising large and medium bone fractures would be within 1 dB of the limit (79 dBA and 79 dBA, respectively). Soft tissue (74 dBA), arthroscopic (73 dBA), and small bone fracture (71 dBA) procedures had the lowest LEP, d. The greatest contributors to noise levels were surgical instruments. The number of people in the room made a significant difference to noise levels (p = 0.032).
CONCLUSIONS: We have established the baseline noise levels in various orthopaedic procedures. Measures should be taken to meet UK regulations. Further research should determine suitable measures for protection from hearing damage for theatre staff and evaluate the risks high noise levels pose to patients.
BACKGROUND: Routine total hip arthroplasty (THA) using a short cemented stem as compared with a standard length cemented stem may have benefits in terms of stress distribution, bone preservation, stem subsidence and ease of revision surgery. Two senior arthroplasty surgeons transitioned their routine femoral implant from a standard 150 mm Exeter V40 cemented stem to a short 125 mm Exeter V40 cemented stem for all patients over the course of several years. We analysed revision rates, adjusted survival, and PROMS scores for patients who received a standard stem and a short stem in routine THA.
METHODS: All THAs performed by the two surgeons between January 2011 and December 2021 were included. All procedures were performed using either a 150 mm or 125 mm Exeter V40 stem. Demographic data, acetabular implant type, and outcome data including implant survival, reason for revision, and post-operative Oxford Hip Scores were obtained from the New Zealand Joint Registry (NZJR), and detailed survival analyses were performed. Primary outcome was revision for any reason. Reason for revision, including femoral or acetabular failure, and time to revision were also recorded.
RESULTS: 1335 THAs were included. 516 using the 150 mm stem and 819 using the 125 mm stem. There were 4055.5 and 3227.8 component years analysed in the standard stem and short stem groups respectively due to a longer mean follow up in the 150 mm group. Patient reported outcomes were comparable across all groups. Revision rates were comparable between the standard 150 mm stem (0.44 revisions/100 component years) and the short 125 mm stem (0.56 revisions/100 component years) with no statistically significant difference found (p = 0.240).
CONCLUSION: Routine use of a short 125 mm stem had no statistically significant impact on revision rate or PROMS scores when compared to a standard 150 mm stem. There may be benefits to routine use of a short cemented femoral implant.
A care service transaction method and system thereof are disclosed. The method comprises the following steps. First, a thermal camera and a control apparatus are disposed in a care place. User's health data is then received, and a care condition is determined based on the health data, and a cost is determined based on the care condition. The control apparatus is set to control the thermal camera based on the care condition, upon reception of paid information. Therefore, the user can buy suitable intelligent care service, such as care in various time period, area or care level, upon his/her demand.
Sedentary behavior is an independent risk factor for chronic disease and premature mortality. Despite a growing awareness of the health risks associated with prolonged sitting, Americans spend upwards of 10 hours per day in a sedentary state. Many leisure-time activities and careers of modern society involve prolonged sitting, necessitating an urgent need to identify strategies that mitigate the health consequences of these behaviors. Recent evidence suggests that interrupting prolonged periods of sitting with short breaks of walking or cycling improve postprandial glucose and lipid handling throughout the day. Thus, relatively small quantities of movement represent an efficacious strategy for improving indices of metabolic health. However, more cost-effective and practical interventions that do not require extra space (i.e. walking) or equipment (i.e. cycling or a treadmill desk) beyond one's immediate sedentary space (e.g. office, desk) would help reduce real and/or perceived barriers of adopting this efficacious disease risk-reduction behavior. A currently understudied consequence of prolonged sitting may also be a desensitization of skeletal muscle's ability to use ingested protein, which overtime can result in detriments to the quantity and quality of this important tissue. Body-weight resistance exercise (RE) can augment the body's ability to use ingested protein to support the maintenance of skeletal muscle mass, and therefore may represent a novel exercise mode to minimize consequences of prolonged sitting. The proposed research will be the first to investigate the influence of interrupting prolonged sitting with short breaks of body-weight resistance exercise (RE) on postprandial glucose and protein metabolism. Importantly, the efficacy of this approach will be directly compared to short breaks of walking, which has previously been reported to improve postprandial glycemia in healthy adults.
BACKGROUND: Optimal reversal agent for direct oral anticoagulant (DOAC)-associated major bleeding has not been described. Before the approval of andexanet alfa (AA) in 2018, 4-factor prothrombin complex concentrate (4F-PCC) was recommended by major guidelines. Currently, AA is recommended as the first-line agent by most guidelines. With a paucity of literature comparing the 2 agents, there is clinical value in assessing hemostatic efficacy and safety of the 2 agents.
OBJECTIVE: This study aimed to evaluate hemostatic efficacy and safety of AA and 4F-PCC in all DOAC-associated major bleedings.
METHODS: A multicenter, retrospective chart review was performed of adult subjects who were admitted for a DOAC-associated major bleeding and received 4F-PCC from February 2018 to May 2019 or AA from May 2019 to September 2021. Some of the exclusion criteria included not receiving a DOAC, receiving multiple reversal agents during the same hospitalization, receiving reversal for any nonmajor bleeding indication, and not receiving the full dose of a reversal agent. The primary outcome was hemostatic efficacy 24 hours after the end of the reversal agent administration. Secondary outcomes included time to administration, hospital mortality, length of stay, need for surgery, and need for additional blood product. Safety outcome was incidence of thrombotic events.
RESULTS: There were 99 subjects included in the 4F-PCC group and 84 subjects in the AA group. Hemostatic efficacy was achieved in 69 subjects (69.7%) in the 4F-PCC group and 63 subjects (75%) in the AA group (P = 0.927). In-hospital mortality was seen in 20 subjects (20.2%) in the 4F-PCC group and 10 subjects (11.9%) in the AA group. Thrombotic events were seen in 7 subjects (7.1%) in the 4F-PCC group and 6 subjects (7.1%) in the AA group.
CONCLUSIONS: There were no significant differences in hemostatic efficacy, in-hospital mortality, and number of thrombotic events between 4F-PCC and AA.
Ballet is as a superlative combination of art and sport that requires high demands musculoskeletal conditioning which works on the development of coordination, balance and associated with efficient strength and flexibility. Balance is a key skill for dance performance for dancers especially for ballet. Ballet dancers use specific balance exercises. It can be expected, that dancers have an advanced sense of awareness for the placement and motion of their bodies. The support surfaces are variable in ballet training, this may also be the reason dancers can better use the information from the somatosensory and vestibular systems. It could be assumed that the effect of ballet training will have a positive effect on postural stability in standing. Postural balance is the act of achieving, maintaining or restoring a state of balance during any posture or activity. It is still unclear whether balance, flexibility and posture in adolescent ballet dancers is different than sedentary adolescent. Therefore, the aim of this study was to assess whether there are differences in balance between adolescent ballet dancers and sedentary adolescent and if these differences are associated with the flexibility and posture. To compare the postural balance between both groups the unipedal standing was chosen, which reduces the quantity of useful and accurate somatosensory information available to the postural control system. Posture analysis and flexibility tests were performed in both groups to compare flexibility and posture on balance. We purpose to compare balance parameters, posture and health quality parameters in adolescent ballet dancers and sedentary adolescent groups.
Repositioning of FDA approved/clinical phase drugs has recently opened a new opportunity for rapid approval of drugs, as it shortens the overall process of drug discovery and development. In previous studies, we predicted the possibility of better activity profiles of flavopiridol, the FDA approved orphan drug with better fit value 2.79 using a common feature pharmacophore model for anti-adipogenic compounds (CFMPA). The present study aimed to investigate the effect of flavopiridol on adipocyte differentiation and to determine the underlying mechanism. Flavopiridol inhibited adipocyte differentiation in different cell models like 3T3-L1, C3H10T1/2, and hMSCs at 150 nM. Flavopiridol was around 135 times more potent than its parent molecule rohitukine. The effect was mediated through down-regulation of key transcription factors of adipogenesis i.e. Peroxisome proliferator-activated receptor gamma (PPARγ), CCAAT/enhancer-binding protein alpha (C/EBPα), and their downstream targets, including adipocyte protein -2 (aP2) and fatty acid synthase (FAS). Further, results revealed that flavopiridol arrested the cell cycle in G1/S phase during mitotic clonal expansion by suppressing cell cycle regulatory proteins i.e. Cyclins and CDKs. Flavopiridol inhibited insulin-stimulated signalling in the early phase of adipocyte differentiation by downregulation of AKT/mTOR pathway. In addition, flavopiridol improved mitochondrial function in terms of increased oxygen consumption rate (OCR) in mature adipocytes. In the mouse model of diet-induced obesity, flavopiridol attenuated obesity-associated adipose tissue inflammation and improved serum lipid profile, glucose tolerance as well as insulin sensitivity. In conclusion, the FDA approved drug flavopiridol could be placed as a potential drug candidate for the treatment of cancer and obesity comorbid patients.
NEW MATERIAL:A monoclonal anti-idiotypic antibody against a monoclonal antibody which specifically reacts with rat bladder cancer and human bladder cancer. USE:Preventive, therapeutic agent and diagnostic for bladder cancers. PREPARATION:For example, N-butyl-N-(4-hydroxybutyl)nitrosoamine is given to a rat to generate bladder cancer and the cancer tissues are a rat of the same system to cause immunization. After final immunization, spleen cells are collected. The spleen cells are fused with mouse myeloma cells and cultured in the HAT culture to prepare a hybridoma. The hybridoma is cloned according the limit dilution method to obtain monoclonal hybridoma. Then, the monoclonal hybridoma is given peritoneally to a mouse, dehydrated to give a monoclonal antibody solution. Further, the solution is given to a rat together with adjuvant to effect immunization and cell-fused with spleen cells in the similar manner to effect cloning. The cloned hybridoma is cultured to give anti-idiotypic type antibody.
Anti-inflammatory mouthwash In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
Objective: The principal objective is to establish the safety and feasibility of bilateral direct current (DC) polarization of the frontal lobes, which may be a useful modality for treatment of frontal lobe cognitive or behavioral deficits. Our secondary objective is to gather preliminary data on whether DC can modulate cognitive and emotion-related functions of the frontal lobes in healthy individuals. Study population: 25 healthy volunteers between the ages of 18 and 80 will be enrolled. Design: The study is a double-blind crossover study with three arms: anodal polarization, cathodal polarization, and sham treatment. Outcome Measures: The primary outcome measures are 1) cognitive function as measured with the CalCAP battery or 2) emotional state as measured with the Profile of Mood States. Secondary outcome measures include tests of emotion-based decision making and social cognition.
INTRODUCTION: With the current trend of increasing noncommunicable diseases (NCD), like hypertension, diabetes and dyslipidaemia worldwide and in Malaysia, a comprehensive study is essential to find the local population's knowledge, attitude and practice towards NCD. Little is known about the indigenous people of Orang Asli's health conditions and health-seeking behaviours towards these chronic diseases. The study aimed to assess knowledge, attitudes and practices (KAP) status towards non-communicable disease and its association with demographic background among Orang Asli adults of the Semelai subgroup in central Pahang, Malaysia.
MATERIALS AND METHODS: A cross-sectional study was conducted among 251 adult Semelai people in Bera district, Pahang. Data was collected through face-to-face interviews to obtain socio-demographic data, KAP towards NCD. Bivariate analysis was performed to test the association between the socio-demographic factor and the KAP score.
RESULTS: Among respondents, 57.4% were female, 82.5% were married, and 46.2% completed primary school. The majority were animism believers (83.3%), self-employed (75.3%) and earning less than RM1000 (87.6%). The respondents' ages ranged from 18 to 77, with a mean age of 41.1 (S.D ± 13.9). The prevalence of known type-2 diabetes mellitus (T2DM), hypertension, and dyslipidaemia was 9.6%, 20.7%, and 8.8%, respectively. About 23.1% of respondents have a family history of chronic disease. Regarding KAP parameters, only 12.7% have good knowledge, and 35.5% have good practice in prevention and treatment. However, more than half (59.8%) have a positive attitude towards chronic diseases. This study also showed that higher household income and education levels were positively associated with higher scores of KAP (p < 0.001).
CONCLUSION: This study presented a low-to-moderate percentage of Orang Asli who have good KAP towards NCD. KAP levels were significantly associated with education levels and household income. Hence, improving education and poverty in the Orang Asli community may successively increase the knowledge level, impart a positive attitude towards NCDs, and improve the practice level toward treatment and prevention.
The aim of our study is to determine if a goal directed program improves weight loss outcomes after sleeve gastrectomy. In the conventional weight loss program, patients will only be given their ideal weight to strive toward after surgery. Routine dietary and physiotherapy/exercise counseling are provided and patients would be educated on their ideal weights based on a BMI of 23. The target weight loss over a 12 month period would be 100% excess weight loss.
The study is a prospective, multi-center, post-market, non-interventional, observational, single-arm study. Subjects with an indication for a PCI according to current European Society of Cardiology (ESC) or national guidelines will be treated with the Ultimaster Nagomi™ in accordance with the intended use. The PCI procedure will be per hospital routine including the option, as per physician preference, to assess the functional severity of the lesion, perform intra-coronary imaging, use lesion preparation devices or to perform a staged procedure. Also, post-procedural anti-platelet medication will be per ESC or national guidelines.

The primary endpoint is Target Lesion Failure (TLF) defined as Cardiovascular Death (CD), Target-Vessel related Myocardial Infarction (TV-MI) and Clinically Driven Target Lesion Revascularization (CD-TLR) at 1 year. Secondary endpoints are a broad set of clinical endpoints defined by the Academic Research Consortium-II to fully characterize the performance of the Ultimaster Nagomi™ stent. Clinical events will be adjudicated by an independent Clinical Events Committee (CEC) to ensure a consistent assessment versus the event definitions. The Data Monitoring Committee (DMC) will simultaneously conduct regular review for accumulating data to ensure proper safety data monitoring. Core lab analysis of the baseline angiograms of bifurcation lesions by Quantitative Coronary Angiography (QCA) will be included. Procedural resource data will be collected for health-economic analysis. Subject reported outcomes will be documented using the EQ-5D-5L questionnaire and the Seattle Angina Questionnaire (SAQ) for the assessment of the quality of life and angina status, respectively.

The study will enroll 3,000 patients from European sites. Follow-up will be 2 years, except for subjects in whom no Ultimaster Nagomi™ stent was implanted and subjects that do not meet the inclusion criteria for a complex PCI as ascertained after the index procedure. These subjects will be followed until discharge.
A compound preparation for treating cervical spondylosis with radiculopathy and a preparation method therefor, the active ingredients thereof consisting of total saponins of radix astragali, total terpenes of ligusticum wallichii, artificial musk, borneol and sinomenine. The dosage form of the present compound preparation comprises granules, pills, capsules and tablets. Also provided are uses for the present compound preparation. The present preparation reduces the amount of intervertebral disc inflammatory factors, reduces the amount of nerve root extracellular growth factors, corrects abnormalities in blood rheology, and improves motor function and gait. It has been shown that the present compound preparation combats inflammation and reduces swelling, inhibits cervical local inflammatory and immune responses, and promotes blood circulation and removes blood stasis. It is effective at benefiting qi and removing blood stasis, and reducing inflammation and relieving pain. The compound preparation has significant curative effects, is safe and non-toxic, is easy to take, and has positive social and economic benefits for the treatment of cervical spondylosis with radiculopathy.
One or more computing devices, systems, and/or methods for determining a time-length of an action are provided. For example, a first event may be detected. Responsive to detecting the first event, a first inquiry may be transmitted in a first direction, using a first device. The first inquiry may be received by a second device. Responsive to receiving the first inquiry, a first reply data packet, comprising an identification number associated with the second device, may be transmitted, using the second device, to the first device. A second event may be detected. Responsive to detecting the second event, a second inquiry may be transmitted in a second direction, using a third device. The second inquiry may be received by the second device. Responsive to receiving the second inquiry, a second reply data packet, comprising the identification number, may be transmitted, using the second device, to the third device.
The invention belongs to the field of traditional Chinese medicines and health-protection food and in particular relates to a beautifying lucid ganoderma composition, medicated liquor and a manufacturing method and application of the medicated liquor. The brand-new composition takes lucid ganoderma as a main component, is prepared by mixing various traditional Chinese medicines and the lucid ganoderma and is used for nourishing the kidney, tonifying the spleen, whitening the skin and beautifying. The composition consists of the lucid ganoderma, hedgehog hydnum, fructus lycii, rhizoma polygonati, oysters, yams, poria cocos, coix seeds, hawthorns, malts, endothelium corneum gigeriae galli, phyllanthus emblica, puerarin, roses, dandelions, lophatherum gracile, gardenia, jujubes and liquorice. The invention also provides the beautifying lucid ganoderma medicated liquor. The manufacturing method of the beautifying lucid ganoderma medicated liquor comprises the steps of decocting the composition in water according to a conventional method and mixing white wine, stevioside and edible glacial acetic acid after mixing and concentrating. The medicated liquor can be directly drunk and has the effects of nourishing the kidney, tonifying the spleen, whitening the skin and beautifying.
Paclitaxel DCB is designed to release anti-proliferative agents to the whole lesion rapidly and homogenously to inhibit excessive neointima proliferation and is associated with rapid healing of endothelium. As a result, DCB therapy reduces the risk of coronary thrombosis. Since only 1 to 3 months duration of dual anti-platelet therapy is required, the bleeding risk associated with prolonged dual anti-platelet therapy (DAPT) is reduced by DCB. Furthermore, there is no permanent residue of foreign bodies in the blood vessels after DCB procedure and this advantage completely eliminates adverse events associated with allergic reactions to metal, polymer and stent fracture. For side branch(SB) with a relatively small lumen in bifurcation lesions, DCB may neglect the lumen loss due to stent scaffolds and cause much less late lumen loss (LLL) than stent therapy does. For main branch(MB), no jailed SBs by the stent and the rate of SB stenosis or even occlusion will be greatly reduced.
It will include oncologists from community clinics who evaluate, prescribe, treat, and actively interact with subjects with NSCLC or soft tissue sarcoma, who have used immuno-oncology (IO) therapies. Oncologists will undergo a telephonic interview for up to 60 minutes.